Human Genome Sciences
Glaxo seals $3 billion acquisition of HGS
July 17, 2012Business Services, Research and Development, Sales and Marketing Benlysta, GSK, Human Genome Sciences, R&D
GlaxoSmithKline has finally sealed the acquisition of Human Genome Sciences, the company with which it co-markets lupus treatment Benlysta. The …
GSK’s bid for Human Genome Sciences rejected
April 19, 2012Sales and Marketing Benlysta, GSK, Human Genome Sciences, mergers and acquisitions
GlaxoSmithKline has launched a takeover bid for Human Genome Sciences for around $2.5 billion, but has been rejected by the …
US approval for GSK’s lupus treatment Benlysta
March 10, 2011Sales and Marketing Benlysta, GSK, GlaxoSmithKline, Human Genome Sciences, Lupus, belimumab, systemic lupus erythematosus
GlaxoSmithKline’s lupus treatment Benylsta has won an historic approval in the US, but will have to prove its safety record …
Novartis drops two drug candidates, takes $600 million hit
October 6, 2010Research and Development Human Genome Sciences, Novartis, candidiasis, hepatitis
Novartis will incur a charge of nearly $600 million after it halted development of investigational drugs for hepatitis C and …
Lonza wins two biologic contracts
July 16, 2010Manufacturing and Production Elusys, Human Genome Sciences, Lonza
Swiss fine chemicals firm Lonza has secured two new contracts for its contract manufacturing division for monoclonal antibodies to treat …
EU regulators to assess potential lupus breakthrough drug
June 8, 2010Sales and Marketing Benlysta, Human Genome Sciences, Lupus
GlaxoSmithKline and Human Genome Sciences have submitted a marketing application to the European Medicines Agency for their new lupus drug. …
